Immix Biopharma, Inc.

Healthcare · Biotechnology · United States

Last price 7.98 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 661.57M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.